Established in 1946, Fidia is an Italian multinational and one of the leading global players in the manufacture of hyaluronic acid-based products. We produce pharmaceutical-grade hyaluronic acid, in a wide range of molecular weights and with peculiar chemical-physical characteristics, depending on the indications and the desired properties of finished product.
Fidia’s approach in developing the Hyal System Line lies in the Weight – Concentration – Technology (W.C.T.) Concept, that is the unique combination of these three variables exploiting different structural and biological properties of HA and enabling each Hyal System Line product to bring out different targeted benefits.
Hyal System ACP is a low molecular weight HA-based gel, stabilized without involving any chemical agent, thanks to the patented ACP (Auto-Crosslinked Polymer) technology, to enable a gradual release of highly pure 200kDa HA.
Hyal System DUO is a new generation, bio-soft filler that combines 75% BDDE crosslinked HMW-HA and 25% auto crosslinked (ACP) LMW-HA.
Our expert panel will share latest findings on LMW-HA and their clinical experiences with Hyal System line.
Q&A
© Fidia Farmaceutici S.p.A.
Via Ponte della Fabbrica 3/A – 35031 Abano Terme (PD) – Italy
Tel. (+39) 049 8232222 Fax (+39) 049 810653
Cap. Soc. € 36.120.000 int. vers. – C.C.I.A.A. PD n. 80793 – Iscr. Reg. Imp. PD
Cod. Fisc. e P. IVA 00204260285
To access this page, please click YES if you are a healthcare professional.
If you are not a healthcare professional, select NO to exit.